m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03245)
Name
3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol
Synonyms
CHEMBL541643
    Click to Show/Hide
Status
Investigative
Structure
Formula
C16H15N3O2S
InChI
1S/C16H15N3O2S/c20-12-3-1-2-11(10-12)15-17-13-4-9-22-14(13)16(18-15)19-5-7-21-8-6-19/h1-4,9-10,20H,5-8H2
InChIKey
XXLAEKOWCYJOKK-UHFFFAOYSA-N
PubChem CID
9901372
TTD Drug ID
D05BPX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PI3-kinase beta (PIK3CB)
Methyltransferase-like 13 (METTL13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
References
Ref 1 N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 2 Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54. doi: 10.1016/j.ejca.2009.03.002. Epub 2009 Apr 1.